LigaChem Biosciences (141080.KQ) Stock Price

LigaChem Biosciences Price

CLOSED
58,400.00
​
Market closed

Revenue has compounded at 42.6% per year over the past 17 years to 141.55 B KRW. LigaChem Biosciences's net margin stands at -52.5%, up from -72.7% several years earlier. Analysts set a median price target of 204,000.00 KRW, implying 249.3% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.

LigaChem Biosciences stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LigaChem Biosciences business model & stock analysis

LegoChem Biosciences, Inc. generates revenue through the development and manufacturing of medicines, medical devices, and medical supplies. The company focuses on new drug development, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory drugs, and antibody-drug-conjugates (ADC). Its business model includes technology transfer, joint research, and research services as key revenue streams. The primary customers are pharmaceutical companies seeking to outsource drug development and manufacturing processes. The firm operates in the pharmaceutical sector with a specialization in innovative drug classes such as ADCs, which are increasingly sought after for targeted cancer therapies. By offering comprehensive research and development services, LegoChem Biosciences supports clients in bringing new therapies to market more efficiently. The company's services are particularly valuable for firms looking to leverage specialized biotechnology expertise without internal R&D infrastructure. LegoChem Biosciences' revenue streams are derived from contracts with pharmaceutical companies for drug development and manufacturing services. The business model emphasizes technology transfer agreements and collaborative research partnerships, which allow the company to monetize its scientific expertise while minimizing capital expenditure on large-scale production facilities.

Frequently asked questions about LigaChem Biosciences

Analysts currently set an average price target of 195,075.00 KRW for the LigaChem Biosciences stock (median: 204,000.00 KRW), implying +243.4 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the LigaChem Biosciences stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect LigaChem Biosciences to generate revenue of 142.80 B KRW and earnings per share of -3,553.34 KRW.

Converted at the current exchange rate, the LigaChem Biosciences share trades at 38.73 EUR (58,400.00 KRW).

The expected revenue of LigaChem Biosciences is 142.80 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of LigaChem Biosciences is -129.36 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of LigaChem Biosciences is currently -16.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the LigaChem Biosciences stock.

The price-to-sales ratio (P/S) of LigaChem Biosciences is currently 14.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the LigaChem Biosciences stock.

The Eulerpool Quality Score for LigaChem Biosciences is 5/10.

The ISIN of LigaChem Biosciences is KR7141080002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of LigaChem Biosciences is 141080.KQ. The ticker symbol is used to trade LigaChem Biosciences shares on the stock exchange.

Fair ValueTerminal
50,808.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
1.22 B KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
May 10, 2013
ISIN
KR7141080002
Cusip
Y5S30B101
Market capitalization
2.01 T KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-16.44
P/Ee 2027
-271.75
P/Ee 2028
2,641.75
P/Ee 2029
—
P/Se
14.89
EV/EBIT
—
P/B Ratio
3.96
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-14.63 %
Last updated Nov 10, 2026, 3:39 AM

LigaChem Biosciences Peer Group

LigaChem Biosciences FIGI

141080:KS · BBG004D9DSR2141080:KQ · BBG004D9DST0